Cue Biopharma Inc
NASDAQ:CUE

Watchlist Manager
Cue Biopharma Inc Logo
Cue Biopharma Inc
NASDAQ:CUE
Watchlist
Price: 0.3648 USD -2.9% Market Closed
Market Cap: $28.7m

Net Margin

-530.7%
Current
Improving
by 1 544.3%
vs 3-y average of -2 075.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-530.7%
=
Net Income
$-37.7m
/
Revenue
$7.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-530.7%
=
Net Income
$-37.7m
/
Revenue
$7.1m

Peer Comparison

Country Company Market Cap Net
Margin
US
Cue Biopharma Inc
NASDAQ:CUE
28.4m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 15 072 companies
9th percentile
-530.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Cue Biopharma Inc
Glance View

Market Cap
28.7m USD
Industry
Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 57 full-time employees. The company went IPO on 2018-01-02. The firm is engineering a class of injectable biologics designed to selectively engage and modulate targeted T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. The company has developed Immuno-STAT (Selective Targeting and Alteration of T Cells) platform, which harness an individual's intrinsic immune repertoire for restoring health while avoiding the deleterious side effects of broad immune activation (for immuno-oncology or infectious disease indications) or broad immune suppression (for autoimmunity and inflammation). The company has developed four biologic series within the Immuno-STAT platform, which includes CUE-100, CUE-200, CUE-300 and CUE-400, each specifically designed through rational protein engineering to possess distinct signaling modules for desired biological mechanisms to be applied across many diseases. CUE-101 is its advanced clinical stage asset.

CUE Intrinsic Value
2.3416 USD
Undervaluation 84%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-530.7%
=
Net Income
$-37.7m
/
Revenue
$7.1m
What is Cue Biopharma Inc's current Net Margin?

The current Net Margin for Cue Biopharma Inc is -530.7%, which is above its 3-year median of -2 075.1%.

How has Net Margin changed over time?

Over the last 3 years, Cue Biopharma Inc’s Net Margin has decreased from -500.6% to -530.7%. During this period, it reached a low of -11 788.6% on Mar 31, 2023 and a high of -438% on Dec 31, 2024.

Back to Top